

Malin Wickström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/102952/publications.pdf>

Version: 2024-02-01

42
papers

1,945
citations

257450

24
h-index

265206

42
g-index

42
all docs

42
docs citations

42
times ranked

3562
citing authors

#	ARTICLE	IF	CITATIONS
1	Aminopeptidase N (CD13) as a target for cancer chemotherapy. <i>Cancer Science</i> , 2011, 102, 501-508.	3.9	293
2	Wnt/ β -catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. <i>Nature Communications</i> , 2015, 6, 8904.	12.8	177
3	Neuroblastoma – A Neural Crest Derived Embryonal Malignancy. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 9.	2.9	166
4	Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. <i>Biochemical Pharmacology</i> , 2007, 73, 25-33.	4.4	99
5	Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2013, 132, 1516-1524.	5.1	99
6	Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs. <i>Journal of Natural Products</i> , 2009, 72, 1969-1974.	3.0	91
7	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. <i>Oncotarget</i> , 2017, 8, 66641-66655.	1.8	65
8	Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2659-2665.	3.0	61
9	Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs <i>In vitro</i> and <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2007, 13, 1036-1044.	7.0	56
10	Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2011, 129, 2958-2965.	5.1	54
11	Molecular mechanisms and therapeutic targets in neuroblastoma. <i>Pharmacological Research</i> , 2018, 131, 164-176.	7.1	53
12	Rho-associated kinase is a therapeutic target in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6603-E6612.	7.1	52
13	The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. <i>Biochemical Pharmacology</i> , 2010, 79, 1281-1290.	4.4	48
14	Image-Based Screening for the Identification of Novel Proteasome Inhibitors. <i>Journal of Biomolecular Screening</i> , 2007, 12, 203-210.	2.6	43
15	Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing Prodrug J1. <i>Journal of Drug Targeting</i> , 2003, 11, 355-363.	4.4	41
16	Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt459.	6.3	41
17	Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability <i>in vitro</i> and impairs tumor growth <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 95135-95151.	1.8	40
18	The novel melphalan prodrug J1 inhibits neuroblastoma growth <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2409-2417.	4.1	38

#	ARTICLE	IF	CITATIONS
19	The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro. <i>Investigational New Drugs</i> , 2008, 26, 195-204.	2.6	36
20	Simvastatin induces apoptosis in human breast cancer cells in a NF κ B-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. <i>Thrombosis Research</i> , 2008, 122, 191-202.	1.7	34
21	In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 697-707.	2.3	33
22	The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2013, 86, 888-895.	4.4	33
23	Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2009, 124, 1227-1234.	5.1	30
24	Lithium protects hippocampal progenitors, cognitive performance and hypothalamus-pituitary function after irradiation to the juvenile rat brain. <i>Oncotarget</i> , 2017, 8, 34111-34127.	1.8	27
25	Significant cytotoxic activity <i>in vitro</i> of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. <i>European Journal of Haematology</i> , 2008, 81, 344-353.	2.2	26
26	Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines. <i>Anticancer Research</i> , 2020, 40, 53-66.	1.1	25
27	Synthesis and Characterization of a Multi Ring Fused 2-Pyridone Based Fluorescent Scaffold. <i>European Journal of Organic Chemistry</i> , 2010, 2010, 6171-6178.	2.4	20
28	Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma. <i>BMC Cancer</i> , 2016, 16, 259.	2.6	20
29	Phenotype-Based Screening of Mechanistically Annotated Compounds in Combination with Gene Expression and Pathway Analysis Identifies Candidate Drug Targets in a Human Squamous Carcinoma Cell Model. <i>Journal of Biomolecular Screening</i> , 2006, 11, 457-468.	2.6	18
30	In vitro and in vivo activity of melflufen (J1) in lymphoma. <i>BMC Cancer</i> , 2016, 16, 263.	2.6	18
31	Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. <i>Biochemical Pharmacology</i> , 2011, 82, 139-147.	4.4	16
32	Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. <i>International Journal of Oncology</i> , 2021, 58, 211-225.	3.3	16
33	Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1526-1536.	4.1	15
34	Inhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth. <i>Cancers</i> , 2020, 12, 73.	3.7	10
35	The impact of S6K1 kinase on neuroblastoma cell proliferation is independent of GLI1 signaling. <i>BMC Cancer</i> , 2014, 14, 600.	2.6	9
36	<i>In vitro</i> antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines. <i>Oncology Letters</i> , 2019, 18, 6249-6260.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance. BMC Cancer, 2013, 13, 374.	2.6	7
38	Wingless/ β -catenin signaling as a modulator of chemoresistance in cancer. Molecular and Cellular Oncology, 2016, 3, e1131356.	0.7	7
39	MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. Cancer Research Communications, 2022, 2, 182-201.	1.7	6
40	SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro. Cancers, 2019, 11, 202.	3.7	5
41	GIT1 protects against breast cancer growth through negative regulation of Notch. Nature Communications, 2022, 13, 1537.	12.8	5
42	Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound. Cell Death and Disease, 2021, 12, 914.	6.3	3